Skip to content

Effect of a Nutritional Supplement With Phytoglycogen on Gut-brain Axis With Focus to Perceived Stress, Mood and Sleep

Effect of a Nutritional Supplement With Phytoglycogen on Gut-brain Axis With Focus to Perceived Stress, Mood and Sleep: a Randomized, Double-blind, Placebo-controlled Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06648980
Enrollment
72
Registered
2024-10-18
Start date
2024-11-04
Completion date
2025-04-30
Last updated
2025-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Perceived Stress

Keywords

perceived stress, phytoglycogen, stress, sleep, mood, gut-brain axis, BDNF

Brief summary

Aim of the study is to investigate the effects of a 8-week supplementation of a phytoglycogen on perceived stress, sleep, mood and emotional wellbeing. Additionally, stress-related biomarker will be evaluated.

Interventions

DIETARY_SUPPLEMENTPlacebo

microcrystalline cellulose; 200 mg /day; 1 capsule/day; 1 capsule daily with breakfast

DIETARY_SUPPLEMENTPhytoglycogen

Phytoglycogen; 200 mg /day; 1 capsule/day; 1 capsule daily with breakfast

Sponsors

Mibelle AG
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Women and men * BMI ≥ 19 and ≤ 30 kg/m² * Subject is in good physical and mental health as established by medical history, physical examination, vital signs, results of biochemistry, haematology * PSQ20 total score ≥33 * Capable and willing to give written informed consent

Exclusion criteria

* Relevant history or presence of any severe medical disorder, potentially interfering with this study (e.g. mal absorption, chronic gastro-intestinal diseases (colitis ulcerosa, Crohn's IBS, peptic ulcers, celiac disease), depression, diabetes, heavy liver disease, immunodeficiency, pancreas insufficiency, acute cancers within last 3 years except basal cell carcinoma of the skin, etc.) * A significant CVD event within last 3 mo. incl. myocardial infarction, stroke, congestive heart failure * Regular intake of drugs possibly interfering with this study (e.g. antidepressants, soporifics) within 3 months prior to study start or during study (stable and controlled L-Thyroxin intake would be allowed) * Regular intake of supplements possibly interfering with this study (e.g. cannabidiol, St. John's wort, melatonin, dietary fiber supplements, probiotics etc.) within 4 weeks prior to study start or during the study (stable vitamin D intake would be allowed) * Vegan nutrition * Smoker > 10 cigarettes / day * Blood donation 4 weeks prior to screening visit and during the study * Known pregnancy, breast feeding or intention to become pregnant during the study * Alcohol or drug abuse * Participation in another clinical study within the last 4 weeks and concurrent participation in another clinical study * Relevant allergy or known hypersensitivity against compounds of the study products * Subjects considered inappropriate for the study by investigators, including subjects who are unable or unwilling to show compliance with the protocol

Design outcomes

Primary

MeasureTime frameDescription
Impact on perceived stress (PSQ20)8 weeks* PSQ = perceived stress questionnaire; * higher scores indicate higher stress levels * the value range is 0-100

Secondary

MeasureTime frameDescription
Impact on mood (ASTS+VT)4 weeksASTS: \- aktuelle Stimmungsskala (ger.) = current mood scale (eng.) VT: \- additional items to calculate subscales 'vigour' and 'tension' seven-point rating scale; value range: 19-133; higher values represent a more negative mood state
Impact on sleep (Sleep Questionnaire B/R)8 weeksSleep Questionnaire (Schlaffragebogen B/R) * 31 questions * refers to the last two weeks * 12 subscales Part B; revised Value range for subscales: 1-5 higher values represent more intense characteristics
Impact on quality of life (SF-36)8 weeks* short form 36 (SF-36) health survey * assessment of quality of life * value range is 0-100 * higher total scores indicate a better quality of life
Impact on perceived stress (PSQ20)4 weeks* PSQ = perceived stress questionnaire; * higher scores indicate higher stress levels * the value range is 0-100
Blood biomarker8 weeksBDNF (brain derived neurotrophic factor) and hsCRP
Impact on emotions (App evaluating emotions)8 weeks* assessment of baseline emotions and triggered emotional change * 5 dimensions are covered
Global Assessment8 weeks* subjective feeling of improvement of perceived stress * answer options: 'yes' or 'no';

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026